Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2023-06-04 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
第六届监事会第二次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the second meeting of the sixth supervisory board of Beijing Northland Biotech Co., Ltd. It includes multiple agenda items related to the company's plan to issue shares to specific investors, including the issuance conditions, pricing, quantity, use of proceeds, and related regulatory compliance. The document also mentions that these resolutions require approval at the shareholders' meeting. The content is focused on corporate governance decisions and capital raising plans, specifically the issuance of shares to specific investors, which is a capital/financing activity. It is not a full financial report, audit report, or earnings release. It is not a simple announcement of voting results but a detailed meeting resolution document. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6475 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2023-06-04 Chinese
第六届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's sixth board meeting, including approval of a proposal for a private placement of shares (向特定对象发行股票), the issuance plan, pricing, use of proceeds, and authorization for the board to handle related matters. It includes voting results, independent directors' opinions, and procedural details. The document is not a full financial report but a formal board resolution announcement related to capital raising and share issuance. It is not a shareholder meeting notice or voting result declaration but a board meeting resolution announcement. This fits the category of Board/Management Information (MANG), as it announces board decisions on management and capital structure matters. The document length and detail support this classification with high confidence.
2023-06-04 Chinese
监事会关于公司向特定对象发行股票相关事项的书面审核意见
Capital/Financing Update Classification · 95% confidence The document is a written supervisory board opinion regarding the company's issuance of shares to specific investors. It discusses compliance with relevant laws and regulations, the company's conditions for issuance, use of raised funds, and shareholder interests. It is not a full financial report but an official statement related to a capital raising activity. The document length is short (1395 characters) and focuses on the issuance of shares to specific parties, which aligns with capital or financing updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-06-04 Chinese
2023年度向特定对象发行股票摊薄即期回报与填补措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a specific stock issuance to particular investors, including the impact on financial metrics, risk warnings, investment project details, and commitments from controlling shareholders and management. It discusses the dilution of immediate returns due to the issuance and the measures to compensate for this dilution. The document references regulatory approvals needed from the Beijing Stock Exchange and the China Securities Regulatory Commission. It is not a full financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a capital/financing update related to a specific equity issuance and its financial and governance implications. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-06-04 Chinese
独立董事关于公司第六届董事会第二次会议的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from independent directors providing their prior approval opinions on various matters related to the company's proposed private placement of shares (向特定对象发行股票). It includes legal and regulatory compliance statements, feasibility analyses, and shareholder return plans for 2023-2025. The content focuses on the independent directors' opinions and approvals ahead of a board meeting, rather than the actual issuance of shares or detailed financial data. The document length is relatively short (2366 characters) and it serves as a pre-approval or endorsement statement rather than a full report or financial disclosure. This fits best under the category of a Regulatory Filing (RNS), as it is a regulatory announcement related to corporate governance and compliance but not a full report, financial statement, or direct capital/financing update filing.
2023-06-04 Chinese
2023年度向特定对象发行股票募集说明书（草案）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书（草案）" which translates to "Offering Prospectus (Draft)" for a 2023 private placement of shares by Beijing Northland Biotech Co., Ltd. It contains detailed information about the stock issuance, including the purpose of the funds, the projects to be funded, the company's business overview, shareholder structure, and product pipeline. The document is lengthy (15,000 characters) and includes detailed financial and operational data related to the capital raising. It is not an announcement of a report publication but the actual offering prospectus document itself. This type of document corresponds to a Capital/Financing Update as it relates to fundraising activities and issuance of shares to specific investors. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-06-04 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.